共 50 条
- [31] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)CANCER RESEARCH, 2024, 84 (09)Rugo, HopeBardia, AdityaCortes, JavierCurigliano, GiuseppeHamilton, ErikaHurvitz, SaraLoibl, SibylleTolaney, SaraKaklamani, VirginiaTonini, GiuliaMatheny, ShannonTheall, Kathy PuvanaO'Shaughnessy, Joyce
- [32] HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trialCANCER MEDICINE, 2023, 12 (24): : 21849 - 21860Ouyang, QuchangWang, YingZhang, JianWu, QiongWei, HongyingLi, ChuanQian, XiaolingHu, Xichun
- [33] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)CANCER RESEARCH, 2024, 84 (09)Ibrahim, NuhadKim, Sung-BaeLin, NancyAwada, AhmadGil, Eva CiruelosTonini, GiuliaVallespir, Bartomeu PizaTheall, Kathy PuvanaHamilton, Erika
- [34] PROGRESSION-FREE SURVIVAL IN PATIENTS WITH ADVANCED OR METASTATIC, HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER TREATED WITH PALBOCICLIB IN COMBINATION WITH FULVESTRANT: A REAL-WORLD STUDYVALUE IN HEALTH, 2022, 25 (07) : S324 - S324Matiz, G. A.Alarcon, B. A.Reyes, Sanchez J. M.Moran, D.Bruges, R.Lombana, M.Manneh, R.
- [35] Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2-LA/mBC)CANCER RESEARCH, 2022, 82 (04)Turner, Nicolas C.Loi, ShereneMoore, Heather M.Chang, Ching-WeiEng-Wong, JenniferBardia, AdityaBoni, ValentinaSohn, JoohyukJhaveri, Komal L.Lim, Elgene
- [36] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella studyANNALS OF ONCOLOGY, 2024, 35 : S372 - S373Rugo, H. S.O'Shaughnessy, J.Cortes, J.Bardia, A.Hamilton, E. P.Hurvitz, S. A.Kaklamani, V.Mchayleh, W.Romero, P. MunozVallespir, B. PizaWasserman, T.Theall, K. P.Tolaney, S. M.
- [37] A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerNPJ BREAST CANCER, 2024, 10 (01)Noguchi, EmiYamanaka, TakashiMukai, HirofumiYamamoto, NaohitoChung, Chi-FengLu, Yen-ShenChang, Dwan-YingSohn, JoohyukKim, Gun MinLee, Kyung-HunLee, Soo-ChinIwasa, TsutomuIwata, HirojiWatanabe, KenichiJung, Kyung HaeTanabe, YukoKang, Seok YunYasojima, HiroyukiAogi, KenjiroTokunaga, ErikoSim, Sung HoonYap, Yoon SimMatsumoto, KojiTseng, Ling-MingUmeyama, YoshikoSudo, KazukiKojima, YukiHata, TomomiKuchiba, AyaShibata, TaroNakamura, KenichiFujiwara, YasuhiroTamura, KenjiYonemori, Kan
- [38] A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)De Vries, ElisabethVenema, Clasina MariekeGlaudemans, Andor W. J. M.Fitzpatrick, LorrainePurandare, DineshHattersley, GaryGarner, Fiona
- [39] H3B-6545+palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Johnston, Stephen R. D.Pluard, Timothy J.Wang, Judy S.Hamilton, Erika P.Song, TingtingRong, YuanxinYamaguchi, KoheiJuric, Dejan
- [40] A phase Ib dose-escalation study of ZN-c5, an oral selective estrogen receptor degrader (SERD), in combination with abemaciclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancerANNALS OF ONCOLOGY, 2021, 32 : S618 - S619Keogh, G. P.Papish, S.Piskorski, W.Ulanska, M.Jackson, B.Suster, M.Ptaszynski, M.Mina, L.